PET in the management of urologic malignancies

被引：47

作者：

Kumar, R ^{[1
]}

Zhuang, HM ^{[1
]}

Alavi, A ^{[1
]}

机构：

[1] Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA

来源：

RADIOLOGIC CLINICS OF NORTH AMERICA | 2004年 / 42卷 / 06期

关键词：

D O I：

10.1016/j.rcl.2004.08.007

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The efficacy of fluorodeoxyglucose-PET (FDG-PET) in initial staging, monitoring response to therapy, and management of many types of cancer has been well documented. Relatively few reports have appeared in the literature describing the use of FDG-PET in urologic tumors. Substantial excretion of FDG through the kidneys interferes with the optimal assessment of urogenital structures and this partly accounts for the uncertainty of its role in these malignancies. This article summarizes the existing data regarding the clinical use of PET with FDG and other tracers in the management of prostate, renal, bladder, and testicular cancers.

引用

页码：1141 / +

页数：14

共 61 条

[1]

Ahlstrom H, 1996, ACTA RADIOL, V37, P180

[2] Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors [J].

Albers, P ;

Bender, H ;

Yilmaz, H ;

Schoeneich, G ;

Biersack, HJ ;

Mueller, SC .

UROLOGY, 1999, 53 (04) :808-811

[3]

Bachor R, 1996, UROLOGE A, V35, P146

[4] Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET [J].

Bokemeyer, C ;

Kollmannsberger, C ;

Oechsle, K ;

Dohmen, BM ;

Pfannenberg, A ;

Claussen, CD ;

Bares, R ;

Kanz, L .

BRITISH JOURNAL OF CANCER, 2002, 86 (04) :506-511

[5] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].

CATALONA, WJ ;

SMITH, DS ;

RATLIFF, TL ;

DODDS, KM ;

COPLEN, DE ;

YUAN, JJJ ;

PETROS, JA ;

ANDRIOLE, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161

[6] 5-YEAR TUMOR RECURRENCE RATES AFTER ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY FOR PROSTATE-CANCER [J].

CATALONA, WJ ;

SMITH, DS .

JOURNAL OF UROLOGY, 1994, 152 (05) :1837-1842

[7] Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer [J].

Chang, CH ;

Wu, HC ;

Tsai, JJP ;

Shen, YY ;

Changlai, SP ;

Kao, A .

UROLOGIA INTERNATIONALIS, 2003, 70 (04) :311-315

[8] Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? -: Results of a study in 50 patients [J].

Cremerius, U ;

Wildberger, JE ;

Borchers, H ;

Zimny, M ;

Jakse, G ;

Günther, RW ;

Buell, U .

UROLOGY, 1999, 54 (05) :900-904

[9]

Cremerius U, 1998, J NUCL MED, V39, P815

[10] 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer [J].

de Jong, IJ ;

Pruim, J ;

Elsinga, PH ;

Vaalburg, W ;

Mensink, HJA .

EUROPEAN UROLOGY, 2003, 44 (01) :32-38

← 1 2 3 4 5 6 7 →